JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

Anesth Analg 1983; 62:1083-1088
© 1983 International Anesthesia Research Society
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goudsouzian, N. G.
Right arrow Articles by Gionfriddo, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goudsouzian, N. G.
Right arrow Articles by Gionfriddo, M.

Safety and Efficacy of Vecuronium in Adolescents and Children

Nishan G. Goudsouzian, MD, Jeevendra J. A. Martyn, MD, Letty M. P. Liu, MD, and Michael Gionfriddo, BA

Received from the Department of Anesthesia, Harvard Medical School at the Masachusetts General Hospital, Boston, Massachusetts and Organon, Inc, West Orange, New Jersey. Presented in part at the International Anesthesia Research Society Meeting, March 1983.

Abstract

The neuromuscular and cardiovascular effects of vecuronium (Norcuron, ORG NC45) were studied in 40 adolescents (10–17 yr) and children (2–9 yr) anesthetized with 1.5% inspired halothane. Ten adolescents and ten children were given 20 µg/kg incremental doses of vecuronium to establish a cumulative dose-response curve during train-of-four stimulation. The ED95 dose was 56 µ/kg in children and 40 µg/kg in adolescents, children being significantly (P < 0.01) more resistant to the neuromuscular effects of vecuronium than adolescents. Another group of 10 children and 10 adolescents received a bolus dose of 80 µg/kg. This dose provided satisfactory conditions for endotracheal intubation with complete suppression of train-of-four response in all adolescents and children within 2 min. Thereafter, the twitch tension recovered to 5% of control twitch height in 18.5 ± 1.5 min, to 25% in 24.4 ± 1.6 min, and to 95% in 43.3 ± 2.1 min. Vecuronium (20–80 µg/kg) did not significantly alter the heart rate or blood pressure nor did it affect kidney or liver function as assessed by routine clinical laboratory tests. Vecuronium is a useful nondepolarizing neuromuscular blocking agent with a short to intermediate duration of action, which can be used safely in children and adolescents.

Key Words: ANESTHESIA: pediatric • NEUROMUSCULAR RELAXANTS: vecuronium.




This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
W. M. Splinter and L. A. Isaac
The Pharmacoeconomics of Neuromuscular Blocking Drugs: A Perioperative Cost-Minimization Strategy in Children
Anesth. Analg., August 1, 2001; 93(2): 339 - 344.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
S. G. Soriano, L. J. Sullivan, K. Venkatakrishnan, D. J. Greenblatt, and J. A. J. Martyn
Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy
Br. J. Anaesth., February 1, 2001; 86(2): 223 - 229.
[Abstract] [Full Text] [PDF]


Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 1983 by the International Anesthesia Research Society.